Vimarsana
Biggest News Aggregation in the World

Page 2 - Morphosy Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosy Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosy Phase Today - Breaking & Trending Today

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 F - Vimarsana News

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 F

Published: January 30, 2024

EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability 30.01.2024 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Mu...

Source: pharmiweb.com
Related Topics:
United StatesEamonn NolanJulia NeugebauerJean Paul KressThomas BiegiXencor IncDrug AdministrationCorporate AffairsEuropean Medicines AgencyExchange CommissionLymphoma SocietyCorporate Communications Investor RelationsDistribution ServicesConstellation Pharmaceuticals IncSys Reports PreliminaryGross MarginReduces Financial LiabilityProduct SalesReduces FinancialChief Executive OfficerMorphosy PhaseAntibody Dependent Cell Mediated CytotoxicityAntibody Dependent Cellular PhagocytosisPrescribing InformationMorphosy Annual Report
Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability -January 30, 2024 at 02:49 am EST - Vimarsana News

Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability -January 30, 2024 at 02:49 am EST

Published: January 30, 2024

EQS-Ad-hoc: MorphoSys AG / Key word: Forecast Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

Source: marketscreener.com
Related Topics:
Product SalesGross MarginReduces FinancialMorphosy Phase
EQS-Adhoc: Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction - adhoc - Börsennachrichten - Vimarsana News

EQS-Adhoc: Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction - adhoc - Börsennachrichten

Published: November 20, 2023

EQSAdhoc MorphoSys AG Key word Study results Ad hoc MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Po

Source: stock-world.de
Related Topics:
United StatesJulia NeugebauerDrug AdministrationDistribution ServicesDynamic International Prognostic Scoring SystemEuropean Medicines AgencyExchange CommissionConstellation Pharmaceuticals IncLymphoma SocietyMorphosy PhaseSpleen Volume ReductionStrong Positive TrendSymptom ReductionSpleen VolumeMeaningful ImprovementsRuxolitinib Combination WasNew Drug ApplicationMarketing Authorization ApplicationFast TrackMorphosy Annual ReportRegulatory AnnouncementsCorporate News